- Drug Pipelines
- March 2021
Global
From €1912EUR$2,000USD£1,639GBP
- Drug Pipelines
- March 2021
Global
From €1912EUR$2,000USD£1,639GBP
- Drug Pipelines
- March 2021
Global
From €2391EUR$2,500USD£2,049GBP
- Drug Pipelines
- July 2020
- 187 Pages
Global
From €1912EUR$2,000USD£1,639GBP
- Drug Pipelines
- July 2020
- 207 Pages
Global
From €1912EUR$2,000USD£1,639GBP
- Report
- November 2023
- 80 Pages
China
From €1721EUR$1,800USD£1,475GBP
- Report
- November 2023
- 242 Pages
China
From €3825EUR$4,000USD£3,278GBP
- Report
- August 2021
- 208 Pages
Global
From €5898EUR$6,168USD£5,054GBP
The Pneumonia Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat bacterial, viral, and fungal pneumonia, as well as other respiratory infections. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Commonly prescribed drugs include antibiotics, antivirals, antifungals, and corticosteroids. In addition, some drugs are used to reduce inflammation and improve breathing.
The Pneumonia Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more